Why competitive LBD inhibition has a structural ceiling
Enzalutamide and darolutamide block androgen receptor signalling by occupying the ligand-binding domain (LBD) and preventing the conformational changes required for nuclear translocation, DNA binding, and coactivator recruitment. Both drugs require an intact, functional LBD for therapeutic activity — any mechanism that bypasses LBD-dependent activation renders them ineffective.
Selective androgen receptor degraders (SARDs) take a categorically different approach. Rather than competing for LBD occupancy, these PROTAC (PROteolysis TArgeting Chimera) heterobifunctional molecules recruit E3 ubiquitin ligases — such as cereblon (CRBN) or VHL — to form a ternary complex with AR. This triggers polyubiquitination of the AR protein and routes it to the 26S proteasome for complete degradation. The result is elimination of AR protein, not merely inhibition of one activation pathway.
A SARD molecule comprises three components: an AR-binding moiety (targeting either the LBD or the N-terminal domain), an E3 ligase-recruiting ligand, and a chemical linker connecting the two. Crucially, the degradation process is catalytic and substoichiometric — a single SARD molecule can trigger multiple degradation cycles, achieving sustained AR depletion at lower concentrations than required for competitive antagonism. This catalytic mechanism is a defining pharmacological advantage over stoichiometric 1:1 competitive binding.
A PROTAC (PROteolysis TArgeting Chimera) is a heterobifunctional molecule that simultaneously binds a target protein and an E3 ubiquitin ligase. The resulting ternary complex triggers ubiquitination of the target, directing it to the 26S proteasome for degradation. Because the PROTAC is not consumed in this process, one molecule can catalyse multiple degradation cycles — a fundamentally different pharmacology from competitive inhibition.
The table below summarises the key mechanistic differences between the two drug classes across pharmacologically relevant dimensions.
| Feature | AR Antagonists (ENZ, DARO) | SARDs (PROTACs) |
|---|---|---|
| Mechanism | Competitive inhibition at LBD | Catalytic protein degradation via UPS |
| AR protein level | Unchanged or increased | Depleted (>80–90%) |
| Target requirement | Functional LBD essential | NTD/DBD sufficient |
| Dose-response | Stoichiometric (1:1 binding) | Substoichiometric (catalytic) |
| Duration of action | Reversible on washout | Event-driven; persists until new AR synthesis |
| Resistance pathway | LBD mutations; AR-V7 bypass; AR amplification | Requires loss of targeted domain or UPS dysfunction |
How LBD mutations convert antagonists into agonists — and why SARDs are immune
LBD point mutations emerge under selective pressure from AR antagonist therapy, altering the binding pocket geometry in ways that convert the antagonist into a partial agonist or reduce its binding affinity. The F876L mutation is the most clinically documented: it converts enzalutamide from antagonist to partial agonist by changing the LBD pocket conformation. T877A, present in 5–30% of castration-resistant prostate cancer (CRPC) cases, broadens ligand specificity and reduces antagonist potency. W741L/C promotes a conformational change that favours agonism under treatment pressure.
The F876L mutation in the androgen receptor ligand-binding domain converts enzalutamide from a competitive antagonist into a partial agonist by altering LBD pocket geometry. Darolutamide retains antagonist activity against F876L-mutant AR due to its distinct chemical structure and binding mode, representing an incremental improvement within the antagonist class.
Darolutamide’s distinct chemical structure and binding mode give it superior activity against F876L-mutant AR compared to enzalutamide — a meaningful incremental improvement. However, all LBD-directed antagonists remain fundamentally vulnerable to mutations that alter LBD structure, because their mechanism depends entirely on maintaining specific LBD interactions. A single nucleotide change is sufficient to generate resistance.
SARDs overcome this through two complementary strategies. First, even LBD-targeting SARDs degrade mutant AR protein rather than attempting competitive inhibition. Mutations that reduce antagonist binding affinity have minimal impact on degradation efficiency as long as sufficient ternary complex formation occurs — the catalytic nature of PROTAC degradation compensates for reduced binding affinity. Second, advanced SARD designs target the AR N-terminal domain (NTD) or DNA-binding domain (DBD), completely circumventing the LBD. These compounds degrade AR regardless of LBD mutations or even LBD absence.
“AR degraders maintained potent activity against enzalutamide-resistant cell lines harbouring F876L and other LBD mutations, achieving greater than 90% AR protein depletion and suppressing AR target gene expression — with DC₅₀ values of 1–5 nM regardless of mutation status.”
Explore the full patent landscape for SARD compounds and AR degrader IP with PatSnap Eureka.
Search AR Degrader Patents in PatSnap Eureka →AR-V7 and AR-V9: the splice variant resistance that antagonists cannot touch
AR splice variants — primarily AR-V7 and AR-V9 — represent the most significant resistance mechanism to all LBD-directed therapies, including both enzalutamide and darolutamide. These truncated AR proteins arise through alternative splicing and lack the entire ligand-binding domain. Because they retain the N-terminal domain (NTD) and DNA-binding domain (DBD), they are constitutively active: no androgen ligand is required for nuclear localisation or transcriptional activity. They drive expression of the same AR target genes as full-length AR, maintaining prostate cancer proliferation entirely independently of any LBD-directed drug.
AR-V7 splice variant is detected in 39–75% of metastatic castration-resistant prostate cancer (mCRPC) patients progressing on abiraterone or enzalutamide. In AR-V7-positive patients, the PSA response rate to enzalutamide is 0–2%, compared with 53% in AR-V7-negative patients, making AR-V7 a strong predictor of primary resistance to AR antagonist therapy.
Enzalutamide and darolutamide have zero mechanistic activity against AR-V7 and AR-V9 for a straightforward structural reason: these splice variants lack the LBD binding site entirely, and constitutive activity means there is no ligand-dependent step to inhibit. The ARMOR3-SV trial, which evaluated galeterone versus enzalutamide in AR-V7-positive patients, showed poor outcomes for both arms. A network meta-analysis found no significant overall survival benefit for AR antagonists in AR-V7-expressing disease. Furthermore, AR-V7 expression increases under AR antagonist selective pressure, creating a bypass pathway that renders continued antagonist therapy futile — a documented cross-resistance mechanism operating through the AKR1C3/AR-V7 axis.
SARDs targeting the NTD or DBD — both domains retained in AR-V7 and AR-V9 — form ternary complexes with E3 ligases and trigger proteasomal degradation of truncated splice variants. In enzalutamide-resistant cell lines expressing AR-V7, AR degraders reduced both full-length AR and AR-V7 protein levels by more than 80%, suppressed AR target gene expression (PSA, TMPRSS2, FKBP5), and inhibited cell proliferation. Bavdegalutamide (ARV-110), the lead clinical SARD, demonstrated selective degradation of AR-V7 in addition to wild-type AR, with sustained target engagement and tumour growth inhibition in AR-V7-expressing xenograft models, as documented by researchers publishing in peer-reviewed oncology journals indexed by NIH/PubMed.
Next-generation AR antagonists share overlapping resistance mechanisms. AKR1C3 upregulation converts weak androgens to potent ligands, reactivating AR despite antagonist presence. AR amplification overwhelms competitive inhibition. AR-V7 expression increases under antagonist selective pressure. SARDs bypass all three: AKR1C3-driven ligand synthesis is irrelevant when AR protein is degraded; catalytic degradation overcomes even high AR expression from amplification; and NTD-targeting SARDs eliminate splice variants that lack the LBD.
Event-driven vs. occupancy-driven pharmacology: the genetic barrier to resistance
The distinction between event-driven and occupancy-driven pharmacology has profound implications for the durability of therapeutic response and the probability of resistance emergence. AR antagonists are occupancy-driven: they require continuous drug presence and LBD occupancy, and their effect reverses rapidly upon drug washout. Resistance emerges when AR signalling is restored despite antagonist presence — through any of several low-barrier genetic events.
For NTD-targeting SARDs, resistance would require deletion of the androgen receptor N-terminal domain — which would eliminate AR transcriptional activity and remove the cancer cell’s AR dependency — or dysfunction of the ubiquitin-proteasome system, which is lethal to cells. Both represent a substantially higher genetic barrier than the single-nucleotide LBD point mutations sufficient to confer resistance to enzalutamide.
SARDs are event-driven: each degradation event is effectively irreversible, and the pharmacodynamic effect persists until new AR protein is synthesised. Resistance to NTD-targeting SARDs faces a much higher genetic barrier:
- NTD deletion would eliminate AR transcriptional activity entirely, removing the cancer’s AR dependency — a self-defeating resistance mechanism.
- UPS dysfunction would disrupt essential cellular protein homeostasis across hundreds of substrates — lethal to cells.
- E3 ligase mutations would affect hundreds of cellular substrates simultaneously — typically non-viable.
By contrast, AR antagonist resistance requires only a single nucleotide change in the LBD (high probability), alternative splicing to generate AR-V7 (moderate-to-high probability), or AR gene amplification (moderate probability). Multiple low-barrier resistance pathways are simultaneously available, explaining the clinical observation that resistance to enzalutamide and darolutamide emerges relatively rapidly in mCRPC — a pattern well-documented in patent filings reviewed through PatSnap’s innovation intelligence platform and in regulatory submissions tracked by EMA.
Preclinical and clinical evidence: from 20,000-fold potency gains to Phase 1/2 data
Preclinical evidence for SARD superiority in resistant models is quantitatively striking. In VCaP cells — a model of AR amplification — an orally bioavailable AR degrader achieved an IC₅₀ of 0.5 nM versus an enzalutamide IC₅₀ greater than 10 μM, representing a more than 20,000-fold improvement in potency. In 22Rv1 cells, which express AR-V7, the same AR degrader achieved 85% growth inhibition compared to 15% for enzalutamide. In vivo, AR degrader monotherapy produced tumour regression in enzalutamide-refractory xenograft models.
Bavdegalutamide (ARV-110), the first-in-class selective androgen receptor degrader (SARD) in clinical development for metastatic castration-resistant prostate cancer (mCRPC), produced PSA declines of ≥50% in 30% of heavily pretreated patients at the optimal dose in Phase 1/2 trials. Circulating tumour cell analysis showed a mean 58% reduction in AR protein levels with corresponding suppression of AR target genes, including in AR-V7-positive patients.
Bavdegalutamide (ARV-110) is the first-in-class SARD to enter clinical development for mCRPC. Phase 1/2 trial results enrolled heavily pretreated patients progressing on enzalutamide and/or abiraterone, including AR-V7-positive patients who are typically excluded from AR antagonist trials. PSA declines of ≥50% were observed in 30% of patients at the optimal dose. Circulating tumour cell (CTC) analysis demonstrated a mean 58% reduction in AR protein levels with corresponding suppression of AR target genes (PSA, TMPRSS2, FKBP5). Activity was observed in both AR-V7-positive and AR-V7-negative patients. The safety profile was generally well-tolerated, with fatigue and nausea as the most common adverse events.
This clinical proof-of-mechanism validates the preclinical hypothesis: targeted AR protein degradation can overcome the resistance mechanisms that define treatment failure with enzalutamide and darolutamide. The clinical-stage data are consistent with the mechanistic framework described by researchers at institutions whose work is catalogued in patent databases tracked by WIPO and reviewed in oncology literature indexed by the National Cancer Institute.
Within the AR antagonist class, darolutamide does represent a meaningful incremental advance: its distinct chemical structure provides superior activity against F876L-mutant AR, reduced blood-brain barrier penetration (lowering CNS side effects), and improved metastasis-free survival in non-metastatic CRPC. However, darolutamide remains completely ineffective against AR-V7 and other splice variants — the same fundamental constraint that limits enzalutamide. The mechanistic ceiling of competitive LBD antagonism applies equally to both drugs.
Analyse the clinical development pipeline for bavdegalutamide and next-generation SARDs with PatSnap Eureka’s drug intelligence tools.
Explore SARD Pipeline in PatSnap Eureka →Implications for treatment sequencing in mCRPC
The mechanistic evidence positions SARDs as the rational next-generation therapy for patients who have progressed on enzalutamide or darolutamide, particularly those with AR-V7-positive disease. The ability to degrade both full-length AR and splice variants, combined with activity against LBD mutants, addresses the primary drivers of acquired resistance to current standard-of-care AR antagonists. The higher genetic barrier to SARD resistance — requiring loss of essential AR domains or UPS dysfunction rather than a single LBD point mutation — also supports potential use earlier in the treatment sequence to delay resistance emergence, a hypothesis currently under clinical investigation.